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Background:  We examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic poly-
peptide (GIP) and glucagon-like peptide 1 (GLP-1) on insulin secretion in women with previous gestational diabetes (pGDM).
Methods:  A 75-g oral glucose tolerance test (OGTT) was conducted on 34 women with pGDM. In addition, 11 women with 
normal glucose tolerance, matched for age, height and weight, were also tested. The insulin, GIP, GLP-1, and glucagon concen-
trations were measured, and their anthropometric and biochemical markers were also measured.
Results:  Among 34 women with pGDM, 18 had normal glucose tolerance, 13 had impaired glucose tolerance (IGT) and 1 had 
diabetes. No significant differences were found in GLP-1 concentration between the pGDM and control group. However, a sig-
nificantly high level of glucagon was present in the pGDM group at 30 minutes into the OGTT. The GIP concentration was ele-
vated at 30 minutes and 60 minutes in the pGDM group. With the exception of the 30-minute timepoint, women with IGT had 
significantly high blood glucose from 0 to 120 minutes. However, there was no significant difference in insulin or GLP-1 concen-
tration. The GIP level was significantly high from 0 to 90 minutes in patients diagnosed with IGT.
Conclusion:  GLP-1 secretion does not differ between pGDM patients and normal women. GIP was elevated, but that does not 
seem to induce in increase in insulin secretion. Therefore, we conclude that other factors such as heredity and environment play 
important roles in the development of type 2 diabetes.
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INTRODUCTION
Gestational diabetes mellitus (GDM) is defined as glucose in-
tolerance of variable severity with onset or first recognition 
during pregnancy [1]. The prevalence of GDM is reported as 
~14% of all pregnancies. Since gestational diabetes causes an 
increase in problems such as macrosomia, birth trauma, neo-
natal hypoglycemia, and obstetrical complications such as Ce-
sarean delivery and preeclampsia, it has been considered as 
one of major metabolic disorders during pregnancy [2]. Addi-
tionally, although the glucose tolerance of most women with 
GDM returns to normal, women with GDM are at an increased 
risk for type 2 diabetes mellitus later in life [2]. In regards to 
attempting to understand the pathogenesis of type 2 diabetes 
in women with GDM, studies for insulin secretion and insulin 
sensitivity in women with previous GDM have been performed. 
When Korean women with previous GDM were measured for 
insulin secretion and insulin sensitivity, even though normal 
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glucose tolerance was maintained after delivery in women with 
GDM, but a significant decrease in their insulin secretion was 
reported compared to women without GDM [3,4]. 
  There is an interaction called the enteroinsular axis, which 
occurs between the intestine and the endocrine pancreas and 
bridges food intake and secretion of pancreatic hormones 
through incretin hormones [5]. Due to these hormones, we 
know that nutrients that are liberated in the intestines as a re-
sult of oral food consumption control the secretion of pancre-
atic hormone secretion (stimulate insulin secretion). The insu-
lin-stimulating effect of the oral glucose load from incretin was 
found to be much larger than the insulin-stimulating effect of 
the intravenous glucose tolerance test [6]. Glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon like pepide1 
(GLP-1) are among the well-known incretin hormones. The 
concentrations of these hormones were reported to be decreased 
or the stimulating effect of insulin secretion was reduced in 
type 2 diabetes, and a 50% reduction of these hormones in the 
sisters of the diabetes patients was reported [7-9]. The decreas-
ing incretin effect of insulin secretion in type 2 diabetes was 
known, while the one of main pathogenesis pathway of type 2 
diabetes, insulin secretion impairment is sometimes assumed 
to be an incretin disorder [8,10]. In terms of insulin resistance 
and insulin secretion disorders, in gestational diabetes, that is 
similar with type 2 diabetes, the likelihood of the failure of in-
cretin effect has been reported. However, using women with 
gestational diabetes as the primary subjects for a study on in-
cretin hormone is considered to be controversial [10,11].
  To find a relationship between insulin secretion capacity and 
concentration of incretin hormones in Korean women with 
GDM, we performed an oral glucose tolerance test (OGTT), 
and measured the concentration of GLP-1, GIP, and glucagon 
during OGTT. 
METHODS 
Method
We recruited women who diagnosed with GDM by NDDG 
criteria from January of 2000 to February of 2003. Thirty four 
volunteers, who had a normal glucose tolerance at 2 months 
postpartum 75-g OGTT, participated in this study. The diag-
nostic procedure and criteria for GDM and diabetes were de-
scribed in great detail in previous studies [12,13].
  We also recruited 11 healthy women with no history of 
GDM as a normal control group based on their age, height, and 
weight. They had no history of diabetes, and no family history 
of diabetes. All study subjects did not have anemia (hemoglo-
bin<11 g/dL), liver dysfunction (2-fold increased liver en-
zyme values), or plasma creatinine elevation (>1.2 mg/dL).
Procedure
The weight, height, and waist circumference were measured in 
a standardized way for all subjects. When measurements were 
collected, subjects were required to remove their shoes and 
wear light clothing. Using a mercury sphygmomanometer, the 
blood pressure was measured three times with a five-minute 
rest between measurements while subjects were in a seated 
position after a 10-minute period. The waist circumference was 
measured at the narrowest point between the lower border of 
the ribs and the iliac crest. The 75-g OGTT was performed in 
the morning after 14 hours of fasting. After sampling venous 
blood, glucose solution (Glucola) was consumed by subjects 
within 5 minutes, and then venous blood samples were col-
lected at 30, 60, 90, and 120 minutes. Plasma glucose concen-
trations were measured using the glucose oxidase method via 
the YSI 2300-STAT glucose analyzer (Yellow Spring Instrument 
Co., Yellow Springs, OH, USA). Using a commercial kit (Linco 
Research, St. Louis, MO, USA), the plasma insulin concentra-
tions were measured using a radioimmunoassay.
  For the purpose of measuring GIP, GLP-1, and glucagon 
concentrations, aprotinin (Trasylol; 20,000 Kallikrein Inhibi-
tor Units/mL, 200 μL per 10 mL blood; Bayer, Leverkusen, Ger-
many) was added to EDTA tubes. The tubes were placed in 
ice-containing coolers, and then after venous blood sampling, 
they were centrifuged at 4°C and stored in a freezer at -72°C. 
GIP and glucagon were measured using a commercially avail-
able enzyme immunoassay kit (Phoenix Pharmaceuticals, Bel-
mont, CA, USA), and GLP-1 measurements were taken using 
a kit that was capable of measuring GLP-1 (7-36) (Phoenix 
Pharmaceuticals). The intra-assay coefficient of variation of 
GIP, GLP-1, and glucagon was 5%, 7%, and 4.8%, respectively, 
and the inter-assay coefficient of variation was 14%, 8%, and 
12%, respectively.
  The insulin resistance index was based on homeostasis mod-
el assessment-insulin resistance (HOMA-IR) [14]. HOMA-IR 
was calculated using the following formula: fasting plasma 
glucose (mmol/L)×fasting insulin (mU/L)/22.5. Total choles-
terol, triglycerides, and high density lipoprotein (HDL) cho-
lesterol were measured using an automatic analyzer (Hitachi 
747; Hitachi, Tokyo, Japan). Insulin secretion capacity was Yu SH, et al.
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evaluated using the HOMA-beta and insulinogenic index (30 
minutes) [14,15]. The SPSS program version 15.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis, and the re-
sults were expressed as mean±standard deviation. Discrete 
variables were analyzed using Kolmogorov-Smirnov analysis 
through non-parametric methods, and continuous variables 
were analyzed using ANOVA. Results with a P value less than 
0.05 were considered to be statistically significant.
RESULTS
According to the criteria of the American Diabetes Associa-
tion, our results from the 75-g OGTT in women with GDM 
revealed 1 woman with diabetes, 13 with impaired fasting glu-
cose or impaired glucose tolerance, and 18 with normal glu-
cose tolerance, and all subjects of the control group were con-
firmed to have normal glucose tolerance as well. There was no 
difference in the age, height, body weight, body mass index, 
and blood pressure between the GDM group and the normal 
control group. The concentration of A1C was higher in the 
GDM group (5.3±0.2% vs. 5.0±0.3%, P=0.02). The total cho-
lesterol, triglyceride, low density lipoprotein (LDL), and HDL 
concentrations in the plasma in both groups were not signifi-
cantly different (Table 1). 
  There was no difference in the fasting glucose levels between 
the GDM group and the normal group (99.1±20.4 mg/dL vs. 
96.3±11.6 mg/dL, respectively, P=0.572). The glucose con-
centration during OGTT in the GDM group was significantly 
higher than that in the normal group at 60 minutes (163.8± 
33.3 mg/dL vs. 133.1±28.8 mg/dL, P=0.009), at 90 minutes 
(144.7±37.7 mg/dL vs. 119.0±24.7 mg/dL, P=0.043), and at 
120 minutes (130.7±28.0 mg/dL vs. 116.2±15.4 mg/dL, re-
spectively, P=0.041). The insulin concentration in the GDM 
group peaked at 60 minutes, and then showed a pattern of grad-
ual decrease. The concentrations of insulin in the subjects from 
the normal control group at 60 minutes and 90 minutes were 
lost, and thus, they could not be measured. However, the insu-
lin concentration of the two groups that were available for 
measurement showed no significant difference.
  For the incretin hormone levels measured at 30-minute in-
tervals during OGTT, there was no significant difference in 
GLP-1 concentrations between the GDM group and the normal 
control group. GIP concentrations were significantly higher in 
the GDM group at 0 minute, and at 60 minutes (Fig. 1). Al-
though the concentration of GLP-1 in the gestational diabetes 
group during the OGTT showed no significant increase, the 
concentration of GLP-1 in the control group from 0 minute 
(43.6±25.9 ng/mL) to 30 minutes (59.8±29.4 ng/mL) showed 
a tendency to increase (P=0.064), and showed a significant in-
crease at 60 minutes (60.3±31.7 ng/mL, P=0.033), and at 120 
minutes (61.0±30.4 ng/mL, P=0.013). Although there was no 
significant increase in the GIP concentration in the GDM 
group, the GIP concentration in the normal group was 28.9 
±12.1 ng/mL at 0 minutes, and it increased to 37.0±9.6 ng/
mL (P=0.002) at 30 minutes, and 38.9±14.0 ng/mL (P=0.000) 
at 90 minutes. 
  There was not a significant difference in the glucagon con-
centration during the OGTT, when compared between two 
groups, but glucagon concentration at 30 minutes was higher 
in the GDM group (40.8±8.7 pg/mL vs. 34.9±3.6 pg/mL, 
P=0.037). However, after adjustment for age (general linear 
model), the GLP-1 and glucagon concentrations were not sig-
nificantly different, and GIP concentration at 0 minute was 
significantly elevated in the GDM group.
  When we compared subject with GDM who were diagnosed 
with impaired glucose tolerance with individuals in the normal 
control group, the plasma glucose concentrations during OGTT 
except the 30-minute mark, were significantly higher in the 
GDM with impaired glucose tolerance group (Fig. 2). Howev-
er, the plasma insulin levels were similar between two groups. 
Table 1. Characteristics of the women with previous gesta-
tional diabetes mellitus (pGDM) and of control subjects  
Parameter pGDM Control P value
No. 34 11
Age, yr 34.2±3.3 25.7±2.1 0.068
Weight, kg 55.2±6.5 55.8±4.6 0.180
Height, cm 157.3±5.2 159.2±4.9 0.625
BMI, kg/m
2 22.5±2.6 22.0±0.9 0.461
SBP, mm Hg 110.6±11.9 107.7±13.5 0.467
DBP, mm Hg 71.4±7.6 67.3±7.5 0.952
HbA1c, % 5.3±0.2 5.0±0.3 0.020
Total cholesterol, mg/dL 171.5±27.2 186.9±24.4 0.490
Triglyceride, mg/dL 113.3±74.1 75.2±35.4 0.289
HDL-C, mg/dL 46.8±8.9 72.4±10.4 0.289
LDL-C, mg/dL 102.0±26.6 99.5±18.4 0.330
No. of pregnancies 0.47±0.66 0 <0.001
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic 
blood pressure; HDL-C, high density lipoprotein cholesterol; LDL-C, 
low density lipoprotein cholesterol.Incretin hormone in previous gestational diabetes mellitus
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Fig. 2. Plasma concentrations of glucose (A), insulin (B), glucagon like pepide1 (GLP-1) (C), glucose-dependent insulinotropic 
polypeptide (GIP) (D), and glucagon (E) after the ingestion of 75-g oral glucose in 13 women with impaired glucose tolerance 
(IGT) (square symbols) and 11 control women (round symbols). Data are presented as means±standard deviation; P values were 
calculated using repeated measures ANOVA. 
aSignificant differences at individual time points (P<0.05 by one-way ANOVA). 
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Fig. 1. Plasma concentrations of glucose (A), insulin (B), glucagon like pepide1 (GLP-1) (C), glucose-dependent insulinotropic 
polypeptide (GIP) (D), and glucagon (E) after the ingestion of 75-g oral glucose in 34 women with a history of previous gestation-
al diabetes mellitus (pGDM) (square symbols) and 11 control women (round symbols). Data are presented as means±standard de-
viation; P values were calculated using repeated measures ANOVA. 
aSignificant differences at individual time points (P<0.05 by 
one-way ANOVA). 
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The GLP-1 concentrations during OGTT did not show a dif-
ference over time, but the GIP concentrations of the GDM 
with impaired glucose tolerance group were significantly high-
er between 0 and 90 minutes. The glucagon concentration at 
30 minutes was higher in the GDM with impaired glucose tol-
erance group (40.2±6.8 pg/mL vs. 34.9±3.6 pg/mL, P=0.032). 
  When the insulin resistance of the GDM group and the nor-
mal control group were compared using HOMA-IR, there was 
no significant difference, but the insulin secretion capacity mea-
sured by the insulinogenic index was significantly low in the 
GDM group, but there was no significant difference in the 
HOMA-beta (Table 2). When the incretin hormone secretion 
during the OGTT was compared using the area under the curve 
(AUC), the AUC_GLP-10-2hr and AUC_GIP0-2hr in the GDM 
group and the normal control groups did not differ, and AUC_
Glucagon0-2hr was higher in the GDM group than in the nor-
mal control group. Additionally, when the blood glucose levels 
and the incretin hormone concentrations over-time-correla-
tion were analyzed, the GIP_30min and the 30-minute plasma 
glucose (r=0.429, P=0.004) had a positive correlation. How-
ever, there was also no significant correlation between blood 
glucose and GLP-1 and glucagon concentrations.
DISCUSSION
In this study, the glucose concentration at 60-120 minutes dur-
ing the OGTT was higher in the GDM group, but there was no 
difference in the insulin concentrations during the OGTT be-
tween the GDM and normal control group. However, when 
insulin secretion capacity using the insulinogenic index was 
compared, the insulin secretion in the GDM group was lower, 
and there was no difference in the insulin resistance measured 
using HOMA-IR. Through our findings that were consistent 
with those of previous studies, we confirmed that the impair-
ment of insulin secretion is the main clinical characteristic in 
women with GDM [3,4,12]. 
  In the patients with type 2 diabetes, the decreased effect of 
GLP-1 and GIP in the insulin secretion are reported in the sev-
eral studies that we reviewed [7,8]. Therefore, incretin hormone 
decrease or impairment appears to be the main mechanism 
underlying insulin secretion disorder in type 2 diabetes. How-
ever, the studies in women with GDM, who are at high risk for 
type 2 diabetes, on GLP-1 and GIP are limited, and the results 
have been inconsistent. In women with GDM, during the ini-
tial 30 minutes of an OGTT, GLP-1 secretion was reported to 
be significantly low, while there was no difference reported in 
the another studies [10,11,16]. 
  In this study, during the OGTT, there was no significant dif-
ference in the GLP-1 concentration between women with GDM 
and normal females. Additionally, the measured GIP concen-
tration in women with GDM was higher than expected. These 
results were consistent with the finding that when Cypryk et 
al. [10] measured the GLP-1 concentration during the OGTT 
in females with GDM, the result was the same as that for nor-
mal females, and there was also no difference in the GIP con-
centration. Even in studies involving the immediate family 
members of patients with type 2 diabetes or individuals with 
impaired glucose tolerance, there was no difference in the GLP 
concentration during the OGTT, and in some cases, it was re-
ported that the GIP value were either similar or were higher 
compared with that of normal control [17,18]. However, in one 
study, there was no significant change of GLP-1 concentration 
in the OGTT, and early (at 30 minutes) GLP-1 concentration 
revealed a decrease of approximately 20% in the GDM group 
[11]. The different findings among studies in women with GDM 
might be due to different clinical characteristics such as eth-
nicity, degree of obesity, and relative risk of developing diabe-
tes. 
  In this study, at fasting and 60 minutes after glucose load 
the measured GIP concentration in subjects with GDM was 
higher than the normal control. This finding suggests that the 
Table 2. Insulin sensitivity/resistance and area under the curve 
(AUC) of the incretin hormones  
pGDM Control P value
HOMA-IR 2.48±1.42 2.31±1.35 0.499
Insulin secretion
HOMA beta cell  
function
120.51±68.47 106.22±49.00 0.436
Insulinogenic index 
(OGTT_30΄) 
11.6±7.2 18.3±10.3 0.035
AUC_GLP-10-2hr 121.7±88.8 103.5±47.7 0.436
AUC_Glucagon0-2hr 83.1±16.5 72.9±5.6  0.003
AUC_GIP0-2hr 87.7±24.3 72.9±22.3 0.079
Insulin resistance determined by homeostasis model assessment 
[HOMA-IR=fasting glucose (X mg/dL÷18) (mmol/L)×fasting insu-
lin (μIU/mL)/22.5].
Insulinogenic index=Δinsulin/Δglucose (U/mol).
pGDM, previous gestational diabetes mellitus; HOMA-IR, homeo-
stasis model assessment-insulin resistance; OGTT, oral glucose toler-
ance test; GLP-1, glucagon like pepide1; GIP, glucose-dependent in-
sulinotropic polypeptide.Incretin hormone in previous gestational diabetes mellitus
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GIP effect on the insulin secretion is reduced in GDM patients. 
When GDM women with impaired glucose tolerance were an-
alyzed separately, the significant increase of the GIP concen-
tration from 0 minutes to 90 minutes during the OGTT was 
also founded. Between the GDM group and control group, 
there was no difference in the fasting plasma glucose, but the 
increase in the GIP concentration in the GDM group was made 
apparent. This finding was consistent with animal knockout 
model. In GLP-1 receptor knockout mice, fasting glucose was 
increased and insulin secretion by the glucose load was de-
creased. However, there was no difference in fasting glucose 
levels, but insulin secretion by the glucose load was decreased 
in the GIP receptor knockout mice [19]. In cases where diabe-
tes occurs in women with GDM, it can be assumed that the ef-
fect of GIP’s insulin stimulation capacity is more impaired than 
that of GLP-1. Additionally, despite the absence of change in 
the concentration of GLP-1, at 30 minutes after the glucose 
load, glucagon concentration in the GDM group, and GDM 
with impaired glucose tolerance group was higher than nor-
mal control group. Inappropriate suppression of glucagon lev-
el was considered to be related to the increase in the glucose 
concentration.
  A limitation of this study was that the GLP-1 concentration 
in the GDM group did not rise significantly during the initial 
phase of the OGTT. However, GLP-1 and GIP concentrations 
during the OGTT increased significantly in the normal con-
trol group. In comparison to the control group, the stimula-
tion of incretin hormone secretion in the GDM group by ris-
ing glucose levels might be weak. So, there might be defect in 
incretin hormone secretion pathway or receptor resistance in 
women with GDM. In addition, the patient groups and the 
control groups did not significantly differ in age, but the con-
trol group had limited information because only small indi-
viduals had a baby. 
  In conclusion, GLP-1 concentration was not different be-
tween women with GDM and healthy women, and GIP con-
centration in women with GDM was higher than the normal 
control, but there was no visible effect on insulin secretion. The 
development of diabetes in women with GDM appears to be 
due to impaired beta cell function that is not related to incretin 
effect.
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